Avacta announces escalation in clinical study of AVA6000 - Drug Informics

Post Top Ad

Wednesday, 29 June 2022

Avacta announces escalation in clinical study of AVA6000

AVA6000 is a novel form of doxorubicin that has been modified using Avacta’s delivery platform to improve safety

from PharmaTimes: News RSS https://ift.tt/zAIbkZ5

No comments:

Post a Comment

Post Top Ad